A new field in glaucoma surgery

Article

Experiences with the iStent trabecular micro bypass revealed

Sustained IOP reduction

Numerous studies have shown that implantation of an iStent results in a sustained reduction in intraocular pressure (IOP) that corresponds to a significant reduction in medication.2 In a terminal washout study comparing cataract surgery alone to cataract surgery with an iStent, the stent group achieved an approximate 3 mmHg greater reduction in pressure than the group that received cataract surgery alone.3 In addition, the iStent group sustained their target pressures with one less medication than the cataractonly group.

I have implanted multiple iStents in phakic and pseudophakic patients, and find that one iStent generally translates to a reduction of one type of medication. When implanting two or three stents, I have seen an approximate 40% drop in pressure, resulting in IOP around 14 mmHg. This corresponds with the prospective, randomized dose response study assessing the IOP lowering effects of one, two or three trabecular micro-bypass stents in 94 subjects, 30 of whom presented at six months.6 Mean baseline IOP after medication washout was 24.9 mmHg in both the one- and twostent groups, and 24.5 mmHg in the threestent group. Mean IOPs at month six were 16.1 mmHg, 13.7 mmHg and 13.6 mmHg respectively. Patients were uncontrolled on two medications when they entered the study, and were controlled on one medication postoperatively.

Importantly, all studies show an overall favourable safety profile with both single and multiple stent implantation. In the dose response study, at day one a one-stent subject had transient hypotony and a threestent subject had a small hyphaema; both events resolved by one week. In the aforementioned study evaluating implantation of two trabecular micro-bypass stents, a small hyphaema in one subject at postoperative week one resolved by one month, and no other complications or adverse events were reported.5

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.